Literature DB >> 27621302

Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients.

Rebecca J Woolley1, Anita Velink1, Richard O Phillips2, William A Thompson3, K Mohammed Abass3, Tjip S van der Werf4, Janine de Zeeuw4, Ymkje Stienstra5.   

Abstract

Buruli ulcer (BU) is one of the 17 neglected tropical diseases for which the World Health Organization has adopted resolutions to improve treatment. BU was previously described as a relatively painless condition; however, recent research has indicated that some patients experience substantial pain. The objective of this study was to explore patients' experiences of pain and their expectations for its treatment. Semistructured interviews were conducted in a BU-endemic region of Ghana. Interviews were held with former BU patients (N = 20) and community controls (N = 19). Former patients were asked about BU-related pain and their expectations for its treatment. The interviews were conducted in October 2014, and were audiotaped, translated and transcribed into English, and then qualitatively analyzed. Of the 20 former BU patients interviewed, 19 (95%) reported experiencing pain, with patients reporting pain as a consequence of the ulcer and wound management. Some participants expressed pain through crying, whereas others did not openly express pain, sometimes because they feared the repercussions of doing so. Patients wanted to receive pain relief; however, many were unable to name a medication. Nonpharmaceutical options were cited as being an alternative. Many BU patients experience pain; however, former patients and community members alike appear to have a limited knowledge about available pain relief. A low-cost alternative to medication may be the use of nonpharmaceutical means for pain relief. Routine pain assessment may reduce patients' fear and unwillingness to express pain. Awareness of such issues will be valuable when implementing a BU pain relief guideline. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27621302      PMCID: PMC5094208          DOI: 10.4269/ajtmh.16-0419

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

Review 1.  Theoretical perspectives on the relation between catastrophizing and pain.

Authors:  M J Sullivan; B Thorn; J A Haythornthwaite; F Keefe; M Martin; L A Bradley; J C Lefebvre
Journal:  Clin J Pain       Date:  2001-03       Impact factor: 3.442

Review 2.  Buruli ulcer.

Authors:  Françoise Portaels; Manuel T Silva; Wayne M Meyers
Journal:  Clin Dermatol       Date:  2009 May-Jun       Impact factor: 3.541

3.  Provision of pain- and symptom-relieving drugs for HIV/AIDS in sub-Saharan Africa.

Authors:  Richard Harding; Richard A Powell; Fatia Kiyange; Julia Downing; Faith Mwangi-Powell
Journal:  J Pain Symptom Manage       Date:  2010-08-04       Impact factor: 3.612

4.  The effect of catastrophizing self-statements on pain perception and the nociceptive flexor reflex (RIII reflex).

Authors:  Ruth Ruscheweyh; Christoph Albers; Annette Kreusch; Jens Sommer; Martin Marziniak
Journal:  Clin J Pain       Date:  2013-08       Impact factor: 3.442

5.  Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.

Authors:  Willemien A Nienhuis; Ymkje Stienstra; William A Thompson; Peter C Awuah; K Mohammed Abass; Wilson Tuah; Nana Yaa Awua-Boateng; Edwin O Ampadu; Vera Siegmund; Jan P Schouten; Ohene Adjei; Gisela Bretzel; Tjip S van der Werf
Journal:  Lancet       Date:  2010-02-03       Impact factor: 79.321

6.  Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study.

Authors:  Junichiro En; Masamichi Goto; Kazue Nakanaga; Michiyo Higashi; Norihisa Ishii; Hajime Saito; Suguru Yonezawa; Hirofumi Hamada; Pamela L C Small
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

7.  Buruli ulcer, Central African Republic.

Authors:  Fanny Minime-Lingoupou; Narcisse Beyam; Germain Zandanga; Alexandre Manirakiza; Alain N'Domackrah; Simeon Njuimo; Sara Eyangoh; Jane Cottin; Laurent Marsollier; Estelle Marion; Francoise Portaels; Alain Le Faou; Raymond Bercion
Journal:  Emerg Infect Dis       Date:  2010-04       Impact factor: 6.883

8.  Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin.

Authors:  Marike Alferink; Janine de Zeeuw; Ghislain Sopoh; Chantal Agossadou; Karibu M Abass; Richard O Phillips; Susanne Loth; Emma Jutten; Yves T Barogui; Roy E Stewart; Tjip S van der Werf; Ymkje Stienstra; Adelita V Ranchor
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

9.  Assessment and Treatment of Pain during Treatment of Buruli Ulcer.

Authors:  Janine de Zeeuw; Marike Alferink; Yves T Barogui; Ghislain Sopoh; Richard O Phillips; Tjip S van der Werf; Susanne Loth; Bouwe Molenbuur; Mirjam Plantinga; Adelita V Ranchor; Ymkje Stienstra
Journal:  PLoS Negl Trop Dis       Date:  2015-09-24

10.  Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease.

Authors:  Fred S Sarfo; Richard O Phillips; Jihui Zhang; Mohammed K Abass; Justice Abotsi; Yaw A Amoako; Yaw Adu-Sarkodie; Clive Robinson; Mark H Wansbrough-Jones
Journal:  BMC Infect Dis       Date:  2014-04-15       Impact factor: 3.090

View more
  3 in total

Review 1.  Pharmacologic management of Mycobacterium ulcerans infection.

Authors:  Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra
Journal:  Expert Rev Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.108

Review 2.  Buruli Ulcer: a Review of the Current Knowledge.

Authors:  Rie R Yotsu; Koichi Suzuki; Rachel E Simmonds; Roger Bedimo; Anthony Ablordey; Dorothy Yeboah-Manu; Richard Phillips; Kingsley Asiedu
Journal:  Curr Trop Med Rep       Date:  2018-09-28

3.  Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.

Authors:  Elizabeth Gyamfi; Charles A Narh; Charles Quaye; Adiza Abbass; Bartholomew Dzudzor; Lydia Mosi
Journal:  BMC Microbiol       Date:  2021-01-05       Impact factor: 3.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.